CVE:COT Cotinga Pharmaceuticals Inc. (COT.V) (COT) Stock Price, News & Analysis C$0.04 -0.03 (-41.67%) As of 10/14/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cotinga Pharmaceuticals Inc. (COT.V) Stock (CVE:COT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get COT alerts:Sign Up Key Stats Today's RangeC$0.04▼C$0.0450-Day RangeC$0.04▼C$0.0452-Week RangeC$0.02▼C$0.12Volume1,000 shsAverage Volume20,281 shsMarket CapitalizationC$769.51 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada. Read More Receive COT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cotinga Pharmaceuticals Inc. (COT.V) and its competitors with MarketBeat's FREE daily newsletter. Email Address COT Stock News HeadlinesV BREAKING NEWS: Visa Inc. Investors that Suffered Losses are Encouraged to Contact Rosen Law about Ongoing Investigation into the Company - VNovember 11, 2024 | markets.businessinsider.comKalVista Pharmaceuticals Inc.May 1, 2024 | wsj.comDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks. July 6 at 2:00 AM | Golden Portfolio (Ad)Lexicon Pharmaceuticals Inc.February 14, 2024 | wsj.comAcumen Pharmaceuticals Inc ABOSNovember 5, 2023 | morningstar.comMSXTP 60 Degrees Pharmaceuticals, Inc.July 21, 2023 | seekingalpha.com8-K: ENANTA PHARMACEUTICALS INCApril 28, 2023 | marketwatch.comIronwood Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationFebruary 18, 2023 | seekingalpha.comSee More Headlines COT Stock Analysis - Frequently Asked Questions How have COT shares performed this year? Cotinga Pharmaceuticals Inc. (COT.V)'s stock was trading at C$0.04 at the start of the year. Since then, COT shares have increased by 0.0% and is now trading at C$0.04. How do I buy shares of Cotinga Pharmaceuticals Inc. (COT.V)? Shares of COT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Cotinga Pharmaceuticals Inc. (COT.V) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cotinga Pharmaceuticals Inc. (COT.V) investors own include Primo Water (PRMW), Cascades (CAS), Aurora Cannabis (ACB), Advantage Lithium Corp. (AAL.V) (AAL), InPlay Oil (IPO), Harvest One Cannabis (HVT) and Exchange Income (EIF). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:COT CIKN/A Webcotingapharma.com Phone+1-519-8585157FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow17.50 Book ValueC($0.18) per share Price / Book-0.20Miscellaneous Outstanding Shares21,986,000Free FloatN/AMarket CapC$769.51 thousand OptionableNot Optionable BetaN/A 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (CVE:COT) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredFINAL HOURS: $9 Income ETF Access VANISHES at MIDNIGHTTHIS IS IT. Your FINAL CHANCE. At midnight, our 82% OFF July 4th deal disappears FOREVER. The countdown ...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cotinga Pharmaceuticals Inc. (COT.V) Please log in to your account or sign up in order to add this asset to your watchlist. Share Cotinga Pharmaceuticals Inc. (COT.V) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.